BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 15987451)

  • 1. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2005; 7(4):R465-9. PubMed ID: 15987451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heikkilä P; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2005; 7(1):R93-100. PubMed ID: 15642173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
    Rayoo M; Yan M; Takano EA; Bates GJ; Brown PJ; Banham AH; Fox SB
    J Clin Pathol; 2009 Oct; 62(10):896-902. PubMed ID: 19622517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.
    Tilanus-Linthorst MM; Alves C; Seynaeve C; Menke-Pluymers MB; Eggermont AM; Brekelmans CT
    Br J Surg; 2006 Aug; 93(8):961-8. PubMed ID: 16758466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management.
    Heidemann S; Fischer C; Engel C; Fischer B; Harder L; Schlegelberger B; Niederacher D; Goecke TO; Doelken SC; Dikow N; Jonat W; Morlot S; Schmutzler RC; Arnold NK
    Breast Cancer Res Treat; 2012 Aug; 134(3):1229-39. PubMed ID: 22535016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
    Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
    Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer immunohistochemical features in young women with BRCA 1/2 mutations.
    Zakhartseva LM; Gorovenko NG; Podolskaya SV; Anikusko NF; Lobanova OE; Pekur KA; Kropelnytskyi VA; Shurygina OV
    Exp Oncol; 2009 Sep; 31(3):174-8. PubMed ID: 19877382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
    Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
    Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short telomeres are frequent in hereditary breast tumors and are associated with high tumor grade.
    Martinez-Delgado B; Gallardo M; Tanic M; Yanowsky K; Inglada-Perez L; Barroso A; Rodriguez-Pinilla M; Cañamero M; Blasco MA; Benitez J
    Breast Cancer Res Treat; 2013 Sep; 141(2):231-42. PubMed ID: 24036693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.
    Spurdle AB; Couch FJ; Parsons MT; McGuffog L; Barrowdale D; Bolla MK; Wang Q; Healey S; Schmutzler R; Wappenschmidt B; Rhiem K; Hahnen E; Engel C; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Wang-Gohrke S; Steinemann D; Preisler-Adams S; Kast K; Varon-Mateeva R; Ellis S; Frost D; Platte R; Perkins J; Evans DG; Izatt L; Eeles R; Adlard J; Davidson R; Cole T; Scuvera G; Manoukian S; Bonanni B; Mariette F; Fortuzzi S; Viel A; Pasini B; Papi L; Varesco L; Balleine R; Nathanson KL; Domchek SM; Offitt K; Jakubowska A; Lindor N; Thomassen M; Jensen UB; Rantala J; Borg Å; Andrulis IL; Miron A; Hansen TV; Caldes T; Neuhausen SL; Toland AE; Nevanlinna H; Montagna M; Garber J; Godwin AK; Osorio A; Factor RE; Terry MB; Rebbeck TR; Karlan BY; Southey M; Rashid MU; Tung N; Pharoah PD; Blows FM; Dunning AM; Provenzano E; Hall P; Czene K; Schmidt MK; Broeks A; Cornelissen S; Verhoef S; Fasching PA; Beckmann MW; Ekici AB; Slamon DJ; Bojesen SE; Nordestgaard BG; Nielsen SF; Flyger H; Chang-Claude J; Flesch-Janys D; Rudolph A; Seibold P; Aittomäki K; Muranen TA; Heikkilä P; Blomqvist C; Figueroa J; Chanock SJ; Brinton L; Lissowska J; Olson JE; Pankratz VS; John EM; Whittemore AS; West DW; Hamann U; Torres D; Ulmer HU; Rüdiger T; Devilee P; Tollenaar RA; Seynaeve C; Van Asperen CJ; Eccles DM; Tapper WJ; Durcan L; Jones L; Peto J; dos-Santos-Silva I; Fletcher O; Johnson N; Dwek M; Swann R; Bane AL; Glendon G; Mulligan AM; Giles GG; Milne RL; Baglietto L; McLean C; Carpenter J; Clarke C; Scott R; Brauch H; Brüning T; Ko YD; Cox A; Cross SS; Reed MW; Lubinski J; Jaworska-Bieniek K; Durda K; Gronwald J; Dörk T; Bogdanova N; Park-Simon TW; Hillemanns P; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Burwinkel B; Marme F; Surovy H; Yang R; Anton-Culver H; Ziogas A; Hooning MJ; Collée JM; Martens JW; Tilanus-Linthorst MM; Brenner H; Dieffenbach AK; Arndt V; Stegmaier C; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Lindblom A; Margolin S; Joseph V; Robson M; Rau-Murthy R; González-Neira A; Arias JI; Zamora P; Benítez J; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Peterlongo P; Zaffaroni D; Barile M; Capra F; Radice P; Teo SH; Easton DF; Antoniou AC; Chenevix-Trench G; Goldgar DE; ; ; ; ;
    Breast Cancer Res; 2014 Dec; 16(6):3419. PubMed ID: 25857409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
    Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.
    Brekelmans CT; Tilanus-Linthorst MM; Seynaeve C; vd Ouweland A; Menke-Pluymers MB; Bartels CC; Kriege M; van Geel AN; Burger CW; Eggermont AM; Meijers-Heijboer H; Klijn JG
    Eur J Cancer; 2007 Mar; 43(5):867-76. PubMed ID: 17307353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients.
    de Bock GH; Tollenaar RA; Papelard H; Cornelisse CJ; Devilee P; van de Vijver MJ
    Br J Cancer; 2001 Nov; 85(9):1347-50. PubMed ID: 11720473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.